Technology Platform

Genome Editing and Epigenetic Modification Platform、Ex vivo Rapid Expansion Platform、Ex vivo Rapid Evaluation Platform for Cell Therapeutics、Non-viral Transfection Platform

Genome Editing and Epigenetic Modification Platform

Using CRISPR editing technology, we can edit and modify the DNA or RNA of human ···

View more
Genome Editing and Epigenetic Modification Platform Genome Editing and Epigenetic Modification Platform

In vitro rapid amplification platform

Rapid large-scale culture of immune cells (T cells and NK cells) and stem cells ···

View more
In vitro rapid amplification platform In vitro rapid amplification platform

In vitro rapid assessment platform for cellular drugs

A rapid in vitro evaluation system utilizing multidisciplinary technologies such···

View more
In vitro rapid assessment platform for cellular drugs In vitro rapid assessment platform for cellular drugs

About Us

Innovating biotechnology for the betterment of human health.

Chengdu MedGenCell Co., Ltd

ChengduMedGenCellCo.,Ltd (hereafter referred to as "the Company") was established in 2015. It is a technology enterprise primarily engaged in the research and development of cutting-edge pre...

  • 2015

    Established in 2015
    • Chengdu MedGenCell Co., Ltd

  • 700+

    700 sq ft GMP laboratory
    • Chengdu MedGenCell Co., Ltd

  • 20+

    Core R&D Team
    • Chengdu MedGenCell Co., Ltd

  • 4Item

    Pipeline under development
    • Chengdu MedGenCell Co., Ltd

  • 2Vice

    Access to top provincial/city innovation and entrepreneurship teams
    • Chengdu MedGenCell Co., Ltd

  • 10+

    National Invention Patent
    • Chengdu MedGenCell Co., Ltd
    Chengdu MedGenCell Co., Ltd

    HONORARY QUALIFICATION

    Awards and Qualifications

    News

    02-01

    MedGenCell's PD-1 Gene-Edited T Cell Injection Approved for Clinical Trials

    According to the CDE official website, MedGencell (Beijing) Co., Ltd(hereinafter referred to as "Med···
    11-17

    Milestone: World's First CRISPR Gene Editing Therapy Approved in the UK!

    On November 16, the world's first CRISPR gene editing therapy (Exa-cel, CASGEVY™) received conditio···
    10-23

    First clinical trial application for gene-edited T-cell drug for solid tumors formally accepted by State Drug Administration (SDA)

    According to the open literature, its “PD-1 gene-edited T-cell injection” IIT phase I clinical tri···
    10-17

    Embracing the 20th National Congress: Talents United with the Party, Pursuing Dreams in the New Era

    On the eve of the 20th National Congress of the Party, the Chengdu Rongdrifters Talent Comprehensive···
    07-02

    Voices of ”Rongpiao" Talents | Deng Tao: Science Has No Borders, But Scientists Have a Motherland

    To celebrate the 100th anniversary of the founding of the Communist Party of China, on June 26th, th···
    02-18

    The article co-authored by Dr. Deng Tao and the GCP Center of the Chinese Academy of Medical Sciences has been published in CANCER CELL, a sub-journal of Cell.

    On January 12, 2021, the article co-authored by Dr. Deng Tao and the National Cancer Center/Cancer H···
    More